Next, we investigated the pharmacological efficacy of KS-133 in a mouse model of psychiatric disorders on the basis of early postnatal activation of VIPR2 (Ago et al., 2015) (Figure 5). The gene discussed is VIPR2; the disease is psychiatric disorder.